Pacer Advisors Inc. Grows Holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Pacer Advisors Inc. lifted its position in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 4.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,755 shares of the medical instruments supplier’s stock after acquiring an additional 73 shares during the quarter. Pacer Advisors Inc.’s holdings in Mesa Laboratories were worth $231,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. FMR LLC boosted its position in Mesa Laboratories by 34.1% during the third quarter. FMR LLC now owns 393 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 100 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Mesa Laboratories during the 3rd quarter valued at approximately $70,000. Sanctuary Advisors LLC acquired a new stake in Mesa Laboratories in the 2nd quarter valued at $183,000. Berry Wealth Group LP purchased a new stake in Mesa Laboratories in the 3rd quarter worth $204,000. Finally, Amalgamated Bank raised its position in Mesa Laboratories by 6.5% during the third quarter. Amalgamated Bank now owns 1,588 shares of the medical instruments supplier’s stock worth $206,000 after acquiring an additional 97 shares during the period. 90.60% of the stock is currently owned by institutional investors and hedge funds.

Mesa Laboratories Stock Performance

Shares of NASDAQ:MLAB opened at $137.27 on Wednesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.70 and a quick ratio of 0.51. Mesa Laboratories, Inc. has a 1 year low of $83.68 and a 1 year high of $152.75. The firm has a market capitalization of $745.38 million, a PE ratio of -3.01 and a beta of 0.83. The business’s 50 day moving average price is $133.26 and its 200-day moving average price is $125.57.

Mesa Laboratories (NASDAQ:MLAB) last announced its earnings results on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.41 by $0.66. Mesa Laboratories had a negative net margin of 107.56% and a positive return on equity of 28.52%. As a group, equities research analysts expect that Mesa Laboratories, Inc. will post 7.39 earnings per share for the current fiscal year.

Mesa Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 17th. Shareholders of record on Friday, February 28th will be paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.47%. The ex-dividend date of this dividend is Friday, February 28th. Mesa Laboratories’s dividend payout ratio (DPR) is -1.40%.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered shares of Mesa Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, November 13th.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.